GRAFORCE
24.1.2023 19:01:49 CET | Business Wire | Press release
Graforce, Germany’s leading provider of zero carbon hydrogen plants, and Kawasaki Gas Turbine Europe GmbH (Kawasaki), a European gas turbine and heat-power cogeneration business, are cooperating for zero-emission heat and power generation. The joint innovative plant concept combines Graforce's methane electrolysis technology (plasmalysis) with hydrogen turbines from Kawasaki. First customer projects for this zero carbon heat and power solution are in the works.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230123005010/en/
Hydrogen turbines and methane electrolysis are game changers for an electricity-independent zero carbon heat-power cogeneration. (Photo: Business Wire)
“Our joint zero-emission plant is a breakthrough for the decarbonization of both, fossil fuels and manufacturing industries”, explains Dr. Jens Hanke, CTO of Graforce. “This technology generates CO2-free high-temperature heat via hydrogen, the carbon black is used as a raw material in production, and – best of all, the process is self-sufficient and does not need further electricity after having been started. This in turn relieves the strain on power grids.”
Decarbonization of industrial processes
The new plant solution generates hydrogen from biomethane, natural gas, LNG or LPG by methane electrolysis technology. The hydrocarbons will remain the initial source, but instead of being burnt, a high frequency plasma splits the hydrocarbons into CO2-free hydrogen and carbon black.
The hydrogen is converted to electricity in Kawasaki's hydrogen gas turbine and reused for hydrogen production in the plasma electrolyzer. The ultra-high temperature CO2-free exhaust gas from the hydrogen gas turbine can be used in production processes in various industries. Companies that previously generated high-temperature heat with natural gas can significantly increase their overall efficiency while reducing their gas and especially electricity costs.
Carbon black is used as a synthetic raw material for industrial production. This way, CO2 can be sequestered long-term in steel, cement or for soil enhancement. For industries which require both high temperatures and large quantities of carbon black for production this process pays off twice – in terms of climate protection and cost-effectiveness.
Beyond industry, this hydrogen-based heat-power cogeneration plant can be used for CO2-free heating in surrounding urban areas.
Both technologies were awarded with the Innovation Award of the German Gas Industry, in 2020 and 2022.
About
Kawasaki Gas Turbine Europe GmbH
The German company, 100% subsidiary of Kawasaki Heavy Industries, LTD. (Japan), providing natural gas and hydrogen gas turbine generator set to improve the energy efficiency for various industries and to contribute the global environmental conservation. http://www.kawasaki-gasturbine.de/en
Graforce GmbH
Graforce is German hydrogen technology company developing and manufacturing Power-to-X plants to decarbonize fossil energies, industrial sectors and the heat, transport and building sectors. The company is currently in a process to expand its strategic partnerships with financial as well as strategic investors to quickly scale its hydrogen technology worldwide. www.graforce.com/EN
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom